SPOTLIGHT -
EP. 1: ESR Mutations and Resistance to Endocrine Therapy in Breast Cancer
EP. 2: CDK4/6 Inhibitors in Hormone Receptor-Driven MBC
EP. 3: FDA Breakthrough Status for Abemaciclib
EP. 4: The Ongoing Role of Everolimus in ER-Positive MBC
EP. 5: The Emerging Role of PI3K Inhibition in Breast Cancer
EP. 6: What is New for HER2 MBC?
EP. 7: Adjuvant TDM-1 and the KRISTINE Trial
EP. 8: PHEREXA Trial in HER2+ Disease
EP. 9: The Emerging Role of Neratinib in HER2+ MBC
EP. 10: Patient Selection for Neratinib in Metastatic Breast Cancer
EP. 11: Neratinib and HER2 Activating Mutations in Breast Cancer
EP. 12: Biosimilar Trastuzumab in HER2-Positive Breast Cancer
EP. 13: Is There a Role for TNBC Subtyping?
EP. 14: Immunotherapy for TNBC
EP. 15: Adjuvant Therapy for Breast Cancer
EP. 16: AC versus TaxAC in High-Risk HER2-Negative MBC
EP. 17: Practice-Changing Results from the MINDACT Trial
EP. 18: Final Thoughts on Advanced Breast Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
